FDA Shutdown Lands Hard On CFSAN-Regulated Industries
This article was originally published in The Rose Sheet
Executive Summary
The federal shutdown interrupts CFSAN’s increasing enforcement against firms marketing violative products, in addition to putting routine facility inspections on hold. FDA retains 8,180 staff members, about 55% of its total, mostly because they could be “paid from carryover funding.”
You may also be interested in...
FDA Warns Foreign Personal-Care Firms For Monograph, GMP Violations
An August letter to Jabones Pardo is the latest in a string of FDA warnings to international firms that market personal-care products for acne treatment, pain relief and other indications in violation of U.S. drug regulations. Warnings to OTC product firms outside the U.S. over the past two years reflect the higher priority FDA has assigned to inspecting international firms.
PCPC, FDA Negotiate Oversight Bill With Possible State-Law Preemption
While acknowledging that there is “a long, long way to go,” PCPC’s John Hurson says industry and FDA have reached a tentative framework for legislation that would update federal cosmetics regulations and possibly preempt state laws, which have become the bane of national cosmetics manufacturers.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.